Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2019

View Archived Issues

RC-01 demonstrates promising efficacy in murine pneumonia and urinary tract infection models

Strictinin reduces TNBC proliferation, survival and motility via inhibition of ROR1

HMCES, in detail

Goldfish genome brings zebrafish insight

Results from phase II study of trabectedin in recurrent grade II or III meningioma

Hanmi presents phase I results for belvarafenib in patients with solid tumors

First-in-human data presented for SRA-737

Cerecor announces promising final results from phase I study of CERC-301

First patient enrolled in phase II study of rimegepant for refractory trigeminal neuralgia

Enrollment begins in phase III study of camrelizumab plus rivoceranib for HCC

Results from phase II study presented for sintilimab in patients with R/R ENKTL

SciFluor Life Sciences divulges KCNQ2/3 activators

Boehringer Ingelheim patents GluN2B negative allosteric modulators

Parkinson's disease starts in gut, moves to brain: study

GlaxoSmithKline synthesizes new IDO1 inhibitors

Esteve Pharmaceuticals patent describes analgesic agents

Shanghai Meiyue Biotech presents new thrombin inhibitors

European Commission approves Libtayo for advanced cutaneous squamous cell carcinoma

Boston Biomedical to discontinue CanStem111P study of napabucasin in pancreatic cancer

Boehringer Ingelheim and Yuhan collaborate on GLP1R/FGF21R agonist for NASH

CD45 could be a novel target for B-cell malignancies

Holy Stone studies CA-102N in first-in-human trial for advanced solid tumors

Early diagnosis of X-linked myotubular myopathy in an infant

PTC Therapeutics and Odylia collaborate on gene therapies for rare inherited retinal diseases

CNOT2 deletion identified as responsible for the phenotypes of the 12q15 microdeletion syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.